The Food and Drug Administration approved the first drug to address the complete symptom profile of Narcolepsy Type 1, a breakthrough for an estimated 200,000 Americans living with the chronic neurological disorder, on Aug. 5.
The approval marks the first time a single FDA-sanctioned medication can treat both excessive daytime sleepiness and cataplexy — sudden muscle weakness — simultaneously. All previous approved treatments addressed only individual symptoms, forcing patients to rely on multiple medications or off-label drug use.
Narcolepsy Type 1 is a lifelong neurological condition that disrupts the brain’s ability to regulate sleep-wake cycles. Patients often experience overwhelming drowsiness during waking hours and sudden episodes of muscle weakness triggered by emotions, which can cause falls and injuries.
The FDA granted the drug priority review status, reflecting the agency’s determination that the condition represented a significant unmet medical need, according to the agency’s announcement.
For decades, narcolepsy patients have managed their condition through combinations of stimulants, antidepressants, and other medications prescribed off-label. The single-drug approval could simplify treatment regimens and reduce the medication burden for patients.
The approval opens commercial access to the medication, though pricing and insurance coverage details were not immediately available. Patient advocacy groups have long called for expanded treatment options for a condition they say has been neglected by pharmaceutical developers.
The milestone is part of the FDA’s ongoing priority review pipeline for neurological conditions, the agency said.